Geen is a platform created with the specific aim of enabling the prototyping of genetic engineering concepts, positioning itself as a significant player in the Biotechnology, Life Sciences, and Pharmaceutical industries. Founded in 2015 and headquartered in Turkey, the company has developed a sophisticated tool that allows for the creation and testing of genetic engineering models, offering essential support to researchers and developers within these sectors.
Despite the promising niche Geen serves, the company's most recent round of investment was a Non Equity Assistance investment on 02 January 2018, with support from Hackquarters. This indicates several years since its last fundraising activity, which may require careful consideration of its current financial and market positioning for future investors. By addressing these challenges, Geen has the potential to continue influencing the genetic engineering landscape through continued innovation and strategic partnerships.